Exposure‐Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis—Analyses of Phase 2b Study to Support Selection of Phase 3 Doses

Lignende værker

• Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials
  af: Klünder, Ben, et al.
  Udgivet: (2017)
• Exposure–Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection
  af: Mohamed, Mohamed‐Eslam F., et al.
  Udgivet: (2019)
• Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I–III Clinical Trials
  af: Klünder, Ben, et al.
  Udgivet: (2019)
• Exposure–Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit–Risk Assessment in Rheumatoid Arthritis
  af: Nader, Ahmed, et al.
  Udgivet: (2019)
• Eosinophil count, serum CCL17/18/26 and immunoglobulin E levels in atopic dermatitis: upadacitinib phase 2 study analysis
  af: Emma Guttman-Yassky, et al.
  Udgivet: (2020-08-01)